Physician

Thomas J Madejski, MD

According to 2025 Medicare claims, Thomas Madejski, MD (NPI: 1356318992) practices internal medicine in the Rochester, NY market, with the plurality of this provider's patient population coming from Orleans, NY. This provider's primary affiliated billing organization is WESTERN NEW YORK MEDICAL PRACTICE P.C. (NPI: 1063790608; TIN: 61-1654232) and primary practice location at 14103-1191. Madejski is affiliated with the Rochester Regional Health ACO, Inc. (ACO ID: A3476) and Honest ACO of New York LLC (ACO ID: D0241), participating under both the MSSP and REACH models.

Madejski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 341 traditional Medicare patients, billed 2,008 HCPCS/CPT codes, and received $114,753 in Medicare payments. The top billing code was 99309 (Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes). Part D data shows 35,592 prescription claims across 1,433 beneficiaries totaling $3,382,159 in drug costs, led by Eliquis (Apixaban). DME data shows 480 claims. Open Payments data shows 4 records totaling $90. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $322,066 to $114,753. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $65,770 and ending at $23,129.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	819	6,475	$322,066
2016	775	5,807	$277,113
2017	713	6,376	$281,330
2018	608	5,549	$232,222
2019	609	5,197	$231,502
2020	729	5,460	$277,635
2021	831	4,738	$256,927
2022	344	1,469	$73,629
2023	368	2,087	$120,975
2024	341	2,008	$114,753

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,594	39,142	$2,484,119
2016	1,454	31,281	$1,890,484
2017	1,423	30,331	$1,957,216
2018	1,319	30,783	$1,898,863
2019	1,220	25,671	$1,653,253
2020	1,301	25,599	$1,725,880
2021	1,321	27,665	$1,822,618
2022	1,214	23,615	$1,887,853
2023	1,344	29,668	$2,961,991
2024	1,433	35,592	$3,382,159

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	304	1,673	$74,231
2016	234	1,062	$36,097
2017	214	918	$24,111
2018	153	783	$30,855
2019	127	669	$23,251
2020	146	803	$28,066
2021	114	912	$37,016
2022	62	620	$33,643
2023	35	475	$29,299
2024	35	480	$27,721

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99309	Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes	66	106	$77
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	189	397	$75
99308	Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, 20 minutes or more	119	553	$51
99307	Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes	98	274	$27
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	86	112	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	599	16,983	$336,036
Rybelsus	Semaglutide	200	8,398	$263,121
Jardiance	Empagliflozin	315	10,842	$217,720
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	256	8,698	$189,140
Xarelto	Rivaroxaban	238	9,349	$175,246

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	18	$8,000
A4238	Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	12	$2,422
A4385	Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each	N	N/R	15	$1,963
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	24	$1,754
A4409	Ostomy skin barrier, with flange (solid, flexible or accordion), extended wear, without built-in convexity, 4 x 4 inches or smaller, each	N	N/R	13	$1,727

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$90	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas J. Madejski, MD?

Tedicare shows public-source Medicare data for Thomas J. Madejski, MD (NPI 1356318992), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas J. Madejski, MD have ACO affiliation data?

Thomas J. Madejski, MD is shown with ACO affiliation data for Rochester Regional Health ACO, Inc. (MSSP, ACO ID A3476) and Honest ACO of New York LLC (REACH, ACO ID D0241).

What billing organization is linked to Thomas J. Madejski, MD?

Thomas J. Madejski, MD is linked to WESTERN NEW YORK MEDICAL PRACTICE P.C. (billing NPI 1063790608) in the available physician profile data.

Does Thomas J. Madejski, MD have Open Payments data?

Thomas J. Madejski, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.